Coeptis Therapeutics
Coeptis Therapeutics is a biopharmaceutical company that focuses on the development and acquisition of cell therapy platforms for patients.
- Company typePublic
- Founded2017
- HeadquartersWexford, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Coeptis Therapeutics does
Coeptis Therapeutics is a clinical stage biotechnology company developing innovative cell therapy platforms for patients with cancer and other debilitating diseases. It focuses on the development and acquisition of pharmaceutical products. Its pipeline is evolving from the partnerships being created with multiple pharmaceutical companies. As the relationships unfold, the product pipeline will be updated accordingly.
Coeptis Therapeutics firmographics
Firmographics- Name
- Coeptis Therapeutics
- Legal name
- Coeptis Therapeutics Holdings, Inc.
- Website
- https://coeptistx.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Coeptis Therapeutics is a biopharmaceutical company that focuses on the development and acquisition of cell therapy platforms for patients.
- Ownership category
- akta.pro rank
Coeptis Therapeutics industry classification
Industry- Product category
- Oncology Cell Therapy Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Coeptis Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Wexford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Coeptis Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Biopharmaceutical Development: Revenue from developing cell therapy platforms for cancer treatment. The company reported $200,681 in revenue in Q2 2025.
- NexGenAI Marketing Platform: AI-powered marketing software and robotic process automation solution generating revenue through managed services agreements ($1.25M) and anticipated recurring monthly revenue ($450,000). Five initial customers signed with total contract value of $1.7 million.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Coeptis Therapeutics product offering
Product offeringCore offering
Coeptis Therapeutics is a biopharmaceutical company developing proprietary allogeneic cell therapy platforms for patients with cancer, including SNAP-CAR (CAR T technology), Stem Cell Expansion technology, the licensed GEAR Cell Therapy Platform from Sweden's Karolinska Institutet, and allogeneic NK cell technology licensed from Deverra Therapeutics. Following the December 2024 acquisition of the NexGenAI Affiliates Network, the company also operates a Coeptis Technologies division offering AI-powered marketing software and robotic process automation to biotech, pharmaceutical, and multi-level marketing industries.
Product overview
Coeptis Therapeutics operates as a hybrid biopharmaceutical and technology company with two distinct business segments. The biopharmaceutical segment focuses on developing proprietary allogeneic cell therapy platforms for oncology, including SNAP-CAR, Stem Cell Expansion technology, and the licensed GEAR Cell Therapy Platform from Sweden's Karolinska Institutet. Following the acquisition of NexGenAI Affiliates Network in late 2024, the company expanded into AI-powered marketing services through its newly created Coeptis Technologies division, offering AI-powered marketing software and robotic process automation solutions to regulated industries including biotech, pharmaceuticals, and multi-level marketing.
Differentiator
Problem solved
Functional benefit
Brands
- NexGenAI Affiliates Network: AI-powered marketing software and robotic process automation solution targeting highly regulated industries including biotech, pharmaceuticals, and multi-level marketing.
- Coeptis Technologies
Products and services
- SNAP-CAR Proprietary allogeneic Chimeric Antigen Receptor (CAR) T cell technology platform developed for oncology applications, aimed at universalizing the treatment of debilitating diseases with safe, effective cell-based therapies accessible to all patients.
- Stem Cell Expansion Proprietary technology platform for expanding stem cells for therapeutic applications, supporting Coeptis's allogeneic cell platform and innovative therapies for cancer treatment.
- GEAR Cell Therapy Platform Cell therapy platform licensed from Sweden's Karolinska Institutet, used as part of Coeptis's proprietary CAR T technology and other innovative cell therapy platforms for cancer treatment.
- Allogeneic NK Cell Technology Allogeneic Natural Killer (NK) cell technology platform licensed from Deverra Therapeutics for cancer treatment, expanded in October 2024 to include pandemic preparedness and emergency use applications.
- NexGenAI Affiliates Network AI-powered marketing software and robotic process automation solution acquired by Coeptis Therapeutics in December 2024, targeting highly regulated industries including biotech, pharmaceuticals, and multi-level marketing. Generates revenue through managed services agreements and recurring monthly contracts.
Companies that use Coeptis Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Coeptis Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Coeptis Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- Z Squared Inc.flagshipMerger agreement where Z Squared becomes a wholly-owned subsidiary of Coeptis, creating the largest publicly traded Dogecoin miner. Transaction valued at $835 million, expected to close in Q3 2025 pending regulatory approval and shareholder consent. Post-merger, combined company renamed Z Squared Inc. with trading under ticker ZSQR on Nasdaq.
- NexGenAI Affiliates NetworkcoreAcquisition of NexGenAI Affiliates Network platform, an AI-powered marketing software and robotic process automation solution targeting highly regulated industries including biotech, pharmaceuticals, and multi-level marketing. Launched Coeptis Technologies division to house the acquired platform.
- Deverra Therapeutics Inc.coreExpanded license agreement to include use of allogeneic natural killer (NK) cell technology for pandemic preparedness, emergency use situations, and treatment of illnesses arising from pandemics or acts of terror or war. Original license expanded to broader therapeutic applications.
- Karolinska InstitutetcoreSwedish research institution that licensed the GEAR Cell Therapy Platform to Coeptis Therapeutics. This partnership provides Coeptis with access to proprietary cell therapy technology for cancer treatment.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Coeptis Therapeutics competitors and assessment
Company assessmentDirect peers
- Allogene Therapeutics: Allogene is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer. It is the most directly comparable peer to Coeptis's allogeneic SNAP-CAR and GEAR platforms, competing in the same off-the-shelf oncology cell therapy space.
- Fate Therapeutics: Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived NK cell and T-cell immunotherapies for cancer. It directly parallels Coeptis's allogeneic NK cell technology licensed from Deverra Therapeutics.
- Nkarta: Nkarta is a clinical-stage biopharmaceutical company engineering allogeneic NK cell therapies for the treatment of cancer. It is a direct competitor in the allogeneic NK cell therapy space aligned with Coeptis's Deverra-licensed NK platform.
- Caribou Biosciences: Caribou Biosciences is a clinical-stage CRISPR genome-editing cell therapy company developing allogeneic CAR-T and CAR-NK cell therapies. Comparable to Coeptis as a clinical-stage allogeneic cell therapy developer with novel cell engineering capabilities.
- Precision BioSciences: Precision BioSciences develops allogeneic CAR T cell therapies using its proprietary ARCUS gene-editing platform. Comparable to Coeptis as a clinical-stage developer of engineered, off-the-shelf cell therapies for oncology.
- Atara Biotherapeutics: Atara Biotherapeutics is a clinical-stage allogeneic T-cell immunotherapy company developing off-the-shelf cell therapies for solid tumors, hematologic malignancies, and autoimmune disease. Peer to Coeptis in allogeneic cell therapy development.
- Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor therapies for solid tumors, including both autologous and allogeneic SPEAR T-cell platforms. Peer to Coeptis in cell therapy for oncology with a similar clinical-stage profile.
- Cellectis: Cellectis is a clinical-stage gene-editing and cell therapy company developing allogeneic CAR-T therapies using its TALEN gene-editing platform. Comparable to Coeptis as a clinical-stage allogeneic cell therapy developer with proprietary gene-editing.
Broad incumbents
- Iovance Biotherapeutics: Iovance is a commercial-stage leader in tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors. A broader incumbent in cell therapy oncology with approved and late-stage products, providing a market-comparable reference for Coeptis.
Emerging players
- Cibus: Cibus is a crop gene-editing company whose core technology of gene editing and cell engineering overlaps with Coeptis's cell engineering platform technologies (SNAP-CAR, gene-editing enabled cell therapies). It is a thematic adjacent peer in gene-editing biology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Coeptis Therapeutics social profiles
Digital presenceCoeptis Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Coeptis Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Coeptis Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Coeptis Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Coeptis Therapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Coeptis Therapeutics
What does Coeptis Therapeutics do?
Coeptis Therapeutics is a biopharmaceutical company developing proprietary allogeneic cell therapy platforms for patients with cancer, including SNAP-CAR (CAR T technology), Stem Cell Expansion technology, the licensed GEAR Cell Therapy Platform from Sweden's Karolinska Institutet, and allogeneic NK cell technology licensed from Deverra Therapeutics. Following the December 2024 acquisition of the NexGenAI Affiliates Network, the company also operates a Coeptis Technologies division offering AI-powered marketing software and robotic process automation to biotech, pharmaceutical, and multi-level marketing industries.
Is Coeptis Therapeutics a public or private company?
Coeptis Therapeutics is a public company. It is classified as public and is currently acquired.
When was Coeptis Therapeutics founded?
Coeptis Therapeutics was founded in 2017. It employs 101 to 250 people.
Where is Coeptis Therapeutics based?
Coeptis Therapeutics is headquartered in Wexford, United States, in the North America region.
How does Coeptis Therapeutics make money?
Two revenue lines are on record. Biopharmaceutical Development is the primary driver. The others are nexGenAI Marketing Platform.
Who are Coeptis Therapeutics's main competitors?
Direct peers on record are Allogene Therapeutics, Fate Therapeutics, Nkarta, Caribou Biosciences, Precision BioSciences, Atara Biotherapeutics, Adaptimmune Therapeutics and Cellectis. Iovance Biotherapeutics is listed as a broad incumbent. Cibus is listed as an emerging player.
Does Coeptis Therapeutics have an API?
No public API is recorded for Coeptis Therapeutics.
What industry is Coeptis Therapeutics in?
Coeptis Therapeutics's product category is Oncology Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.